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Abstract
Background: Limited research has been performed that focused on the diagnosis of the underlying
cause of anaemia of chronic disease (ACD) in general practice or on prevalence data of the
underlying causes of ACD in general practice, although this is one of the most common types of
anaemia.
Aim: To clarify the diagnostic strategies of GPs in patients newly diagnosed with ACD and to
determine the most common underlying causes.
Design & setting: Retrospective cohort study.
Method: Patients newly diagnosed with ACD were selected based on laboratory criteria. ACD was
defined as confirmed anaemia and ferritin levels above 100 mg/l combined with decreased iron and/
or reduced transferrin. Additional medical information on patients was obtained from the electronic
medical files of the GP and/or the referral hospital.
Results: Of the 267 analysed patients with ACD, additional investigations were performed in 205
patients (77%); in 31 patients (12%) the cause was apparent at the time of diagnosis, and for 31
patients (12%) no additional investigations were requested. In 210 (79%) of the 267 patients, an
underlying cause was established, with infection (n = 68, 32%), autoimmune disease (n = 51, 24%)
and malignancy (n = 48, 23%) as the most frequently observed etiologies. In 35 (13%) of the ACD
patients, oral iron supplementation was prescribed by the GP. This was mainly done in patients
with severe anaemia or less enhanced ferritin levels.
Conclusion: For most patients with newly diagnosed ACD, the GP undertakes additional
investigations to establish underlying causes. However, the cause of ACD remains unknown in a
small proportion of patients. The use of oral iron supplementation in these patients requires
caution.
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How this fits in
This study provides an overview of the most commonly requested additional investigations by GPs
and presents the prevalence of the most common underlying causes of ACD in general practice.
ACD is often observed in general practice. Establishing the underlying cause of ACD is essential,
since this condition can lead to reduced quality of life and/or increased risks related to possibly det-
rimental underlying diseases. Finally, this study demonstrates that 13% of ACD patients still receive
oral iron supplementation, mainly those patients with severe anaemia and less enhanced ferritin
levels.
Introduction
Anaemia is a common finding in general practice and is associated with increased mortality, physical
and cognitive decline, collapse, fractures, frailty, cardiovascular events, and reduced quality of
life.1,2 ACD is one of the most common types of anaemia.3–6 This type of anaemia can be caused by
a variety of conditions, including acute and chronic infections, chronic diseases, autoimmune disor-
ders, acute trauma, surgical interventions, renal failure, heart failure, and malignancies.7–13
ACD is described as a functional iron deficiency caused by elevated hepcidin levels, which implies
that oral iron supplementation is unnecessary.14–16 Patients with ACD aged 50 years have a relative
risk for mortality of 1.48 compared to adults without anaemia.17 To ensure proper treatment of
ACD, the underlying cause needs to be elucidated and treated. If the cause is not clear, additional
investigations are required.2,5,15,16,18,19 These steps require active participation of the GPs involved
with patients with ACD in general practice.
The National Institute for Health and Care Excellence (NICE) published guidelines on the manage-
ment and treatment of anaemia in patients with chronic kidney disease, which is an underlying cause
often observed in ACD patients.20 Besides these guidelines, there is not much research available
focusing specifically on the diagnosis of the underlying cause of ACD in general practice, or on prev-
alence data of the underlying causes of ACD in general practice. Therefore, this study aims to clarify
the diagnostic strategies employed by GPs for their patients with ACD and provides an overview of
the underlying causes as established by GPs and/or medical specialists.
Method
Patient inclusion
Patients were recruited as part of a transmural project aimed at anaemic patients aged 50 years.
The main goal of the project is to improve the care for anaemic patients, and it has been running
since 2007.21
In patients presenting to one of the 63 participating GPs with symptoms indicative of anaemia, an
extensive laboratory protocol was performed that consisted of haemoglobin, mean corpuscular vol-
ume, C-reactive protein and/or erythrocyte sedimentation rate, vitamin B12, creatinine, ferritin, folic
acid, lactate dehydrogenase, transferrin, reticulocytes, leukocytes, thrombocytes, and serum
iron.18 Anaemia was defined as haemoglobin 13.7 g/dL (8.5 mmol/L) for males and 12.1 g/dL
(7.5 mmol/L) for females. ACD was defined as confirmed anaemia and ferritin 100 mg/l combined
with decreased serum iron (<14 mmol/L for males and <10 mmol/L for females) and/or reduced trans-
ferrin (below the lower limit of the reference interval).21,22 As part of the transmural project, a com-
ment was added to the laboratory results alerting GPs to the most likely cause of anaemia.
For the present study, patients diagnosed with ACD were retrospectively selected from the large
database that was compiled between 1 February 2007 and 1 February 2013.
Data collection
Clinical data was extracted from the electronic medical files of the GPs and referral hospital. Data
could only be collected on the basis of the willingness of the GP to participate in the study and the
availability of the data in electronic documentation. If these conditions could not be met, the patient
was excluded from the study (n = 564) (Figure 1).
Since patients were recruited over a 6-year period, the length of follow-up varied considerably.
The end of follow-up was recorded as the date of data collection, or the date of the last available
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documented data (due to patients changing their GP in case of relocation or migration). If the
patient had died before the moment of data collection, the date of death was recorded as the end
of follow-up.
Collected clinical information consisted of all diagnostic investigations ordered by GPs, including
those requested in consultation with a medical specialist, from the moment of discovery of ACD until
the diagnosis of the underlying cause or the first outpatient visit to the referral hospital. These inves-
tigations were defined as ‘additional investigations’. In addition, all underlying causes of ACD (those
diagnosed by the GP and those diagnosed by the referral hospital’s medical specialist) were regis-
tered. If the patient was known to suffer from diabetes, chronic lung disease, or heart failure, and no
other underlying cause of ACD could be established, these diseases were assigned as the underlying
cause of ACD.7–13 Any prescription of oral iron supplementation, as well as the time (in weeks) from
the confirmation of ACD to the establishment of the underlying cause were also recorded.
Definitions
Guidelines published by the Dutch College of General Practitioners in 2003 (revised in 2014) recom-
mend handling newly diagnosed ACD in general practice as follows:
1. further diagnostic investigations to clarify the underlying illness (unless an underlying cause is
already known); and
2. no oral iron supplementation.16
In the present study this was defined as ‘current recommendations’.
Figure 1. Flow diagram of the selection of study patients.
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Statistical analysis
The study population was characterised by standard descriptive statistics. Comparisons of the
included and excluded patients were performed using the c2 test and independent samples t-test
(as appropriate). Differences in mean haemoglobin levels between patients referred and not referred
to a medical specialist after establishment of ACD were tested using an independent samples t-test.
Factors associated with the prescription of oral iron supplementation were analysed using the c2
test, independent samples t-test, and multivariable logistic regression analysis. The independent var-
iables in the logistic regression were age, sex, haemoglobin, and ferritin. Haemoglobin and ferritin
were dichotomised according to the median of those variables. In addition, the same univariable
and multivariable analyses were used to investigate factors associated with the recommended diag-
nostic and therapeutic strategy of patients with ACD.
A two-sided P-value 0.05 was considered statistically significant. Data were analysed using the
SPSS for Windows (version 24).
Results
Patient characteristics
Between 1 February 2007 and 1 February 2013, patients with newly diagnosed anaemia were
included in a large transmural project.21 In 831 (33%) of these 2513 patients, the anaemia was
defined as ACD based on predefined laboratory criteria and evaluated by experienced clinical chem-
ists. All tests were performed in the clinical chemistry laboratory of the Albert Schweitzer Hospital.
Because of lack of consent of the GP due to time restraints and loss of follow-up, a total of 267
patients (32%) with newly diagnosed ACD were finally available for the analysis (Figure 1). Charac-
teristics of the study group are presented in Table 1.
No significant difference was found between the included patients and the non-participants
regarding sex (P = 0.11), but a small difference in age was found (mean age of included patients
74.3 years versus 73.5 years in non-participants, P = 0.05). For both males and females, no significant
differences in haemoglobin, ferritin, or transferrin levels were found between the included patients
and non-participants (data not shown). In addition, the included patients demonstrated a signifi-
cantly lower serum iron level compared with the non-participants (P = 0.003 for males, P = 0.01 for
females).
Table 1. Characteristics of the study population (n = 267).
Mean ±SD Reference value
Sex 148 male
119 female
Age, years 74.3 ±10.5
Male 72.3 ±10.7
Female 76.7 ±9.7
Haemoglobin, g/dl 11.8 ±1.3
Male 12.4 ±1.1 13.7–17.7
Female 11.0 ±1.0 12.1–16.1
Transferrin, g/l 1.9 ±0.4 2.0–3.6
Ferritin, mg/l
Male 445 ±325 25–250
Female 379 ±373 20–150
Serum iron, mmol/l
Male 7.1 ±3.7 14–28
Female 5.9 ±3.4 10–25
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Additional investigations by GPs
In 205 (77%) of the 267 included patients with newly established ACD, additional investigations were
requested by GPs to clarify the underlying illness (Table 2). Moreover, in 78 patients multiple investi-
gations were performed, resulting in a total of 311 investigations. The most frequently requested
additional investigations were chest X-ray (24%), referral to an internist (21%), and referral to the
emergency room (10%). The cause was already apparent at the time of diagnosing the ACD in 31
patients (12%), mostly due to diabetes mellitus (39%) and autoimmune diseases (32%). For 31
patients (12%), no additional investigations were requested, even though the cause of ACD was not
clear. Patients who were referred to a medical specialist (n = 145, 54%), either at initial diagnosis or
after additional investigations by the GP, had a mean haemoglobin level of 11.7 (range 8.1–13.5) g/
dl compared with 11.8 (range 7.9–13.5) g/dl in patients who were not referred (P = 0.378).
Underlying causes of ACD
In 210 (79%) patients an underlying cause of ACD was determined, most frequently infection (n =
68, 32%), autoimmune disease (n = 51, 24%), and malignancy (n = 48, 23%) (Table 3).
In 154 patients (58%), the median time from presentation with anaemia to clarification of the
underlying cause could be collected; this was 2 weeks (range 0–48). Of these 154 patients, the
underlying cause was established within 1 week for 66 (43%), and within 4 weeks after presentation
for 103 patients (67%). Further information is available from the authors on request.
Current guideline recommendations
In 205 (77%) patients, the GP acted according to the current Dutch guidelines (additional investiga-
tions to clarify the underlying illness causing ACD [unless an underlying cause was already known],
and no oral iron supplementation prescribed). These recommendations were adhered to more
Table 2. Data on established cause and recorded investigations
Frequency, n (%)






Ultrasound, abdomen 28 (9.0)
CT scan, abdomen/thoraxb 12 (3.9)
Endoscopy











a Only physical examinations directly related to a diagnosis of the underlying cause were noted. b CT scan was always requested
in consultation with a medical specialist. CT= computed tomography.
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frequently in patients with a high ferritin level, that is >324 mg/l (OR 2.46; 95% confidence interval
[CI] = 1.33 to 4.52), as shown in Table 4. In addition, less frequent implementation of the recommen-
dations in older patients (OR 0.97, 95% CI = 0.94 to 1.00) and patients with more severe anaemia,
that is haemoglobin <11.8 g/dl (OR 0.47, 95% CI = 0.2 to 1.03) was detected, but these associations
were not statistically significant.
Oral iron supplementation
Of all 267 patients, 35 (13%) received oral iron supplementation despite being diagnosed with ACD
and demonstrating ferritin levels 100 mg/l. Severe anaemia (haemoglobin <11.8 g/dl) and less
Table 3. Underlying causes of anaemia of chronic disease
Additional
investigations, n (%)
(n = 205; 77%)
Underlying disease already
apparent, n (%)
(n = 31; 12%)
No additional investigation, no apparent
cause, n (%)






179 (87) 31 (100) 0 (0) 210 (79)
Autoimmune disease 41 (23) 10 (32) – 51 (24)
Infection 68 (38) – – 68 (32)
Renal failure 4 (2) – – 4 (2)
Recent operation 2 (1) 1 (3) – 3 (1)
Malignancy 44 (25) 4 (13) – 48 (23)
Diabetes 7 (4) 12 (39) – 19 (9)
Heart failure 5 (3) 2 (7) – 7 (3)
Chronic lung disease 4 (2) 1 (3) – 5 (2)
Other causesa 4 (2) 1 (3) – 5 (2)
No cause established 26 (13) 0 (0) 31 (100) 57 (21)
Percentage of underlying causes is calculated from the total number of causes established in each subgroup. aSuch as liver cirrhosis, haematoma, and alcohol abuse.
Table 4. Factors associated with implementation of the current recommendations and prescription of oral iron supplementation.
Univariate analysis Multivariate analysis
Percentage or mean difference (95% CI) Odds ratio (95% CI)
Recommendations
Age, years 3.63 (0.65 to 6.60) 0.97 (0.94 to 1.00)
Female 84.0 Reference category
Male 91.9 0.82 (0.38 to 1.75)
Haemoglobin 11.8 g/dl 90.4 Reference category
Haemoglobin <11.8 g/dl 86.6 0.47 (0.21 to 1.03)
Ferritin >324 mg/l 92.5 Reference category
Ferritin 324 mg/l 84.3 2.46 (1.33 to 4.52)
Oral iron supplementation
Age, years -1.29 (-5.05 to 2.47) 1.00 (0.97 to 1.04)
Female 15.1 Reference category
Male 11.5 2.00 (0.83 to 4.83)
Haemoglobin 11.8 g/dl 6.4 Reference category
Haemoglobin <11.8 g/dl 19.0 4.97 (1.82 to 13.62)
Ferritin >324 mg/l 8.3 Reference category
Ferritin 324 mg/l 17.9 2.30 (1.06 to 4.99)
CI = confidence interval
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enhanced ferritin levels (<324 mg/l) were associated with a higher probability of oral iron supplemen-




This study provides a representative overview of the diagnostic strategies employed by GPs for their
patients with ACD and an overview of the underlying causes as established by GPs and/or medical
specialists. Additional investigations were requested in 77% of the analysed 267 ACD patients. The
most frequently requested additional investigations were chest x-ray (24%), referral to an internist
(21%), and referral to the emergency room (10%). The underlying cause of ACD was established in
79% of these patients, with the most common causes being infection (in 32%), autoimmune disease
(in 24%), and malignancy (in 23%). The median time from presentation with anaemia to clarification
of the underlying cause of ACD was 2 weeks. The prescription of oral iron supplementation in
patients with ACD is not recommended and requires caution.14–16
Strengths and limitations
A possible limitation of this study is related to the recruitment of patients. Of all GPs participating in
the project, about one-third declined participation (mainly due to time constraints). However, the
group of newly diagnosed ACD patients not included in this study presented no significant differ-
ence in sex, or haemoglobin, ferritin, or transferrin levels compared with those included in the analy-
ses. In addition, because a difference in age and in serum iron levels was observed between the
groups, all analyses were corrected for these two variables. Another limitation is the retrospective
design of the study, which can lead to differences in the completeness of individual GPs’ medical
reports and, perhaps, to loss of patient information, such as the reason to decline additional investi-
gations after establishment of ACD.
Strengths of the study include a large sample size of representative patients providing a realistic
overview of patients with ACD in general practice. In addition, patients were selected based on
well-defined laboratory criteria, making these results generalisable to other countries. Finally, the
content of the Dutch guidelines used for handling newly diagnosed patients with ACD is also widely
accepted in other guidelines worldwide.2,20,23
Comparison with existing literature
This study demonstrated that 77% of the ACD patients received additional investigations after
establishment of the ACD, with the most common strategy being referral to a medical specialist
(47%). This relatively large proportion of referrals might be because the diagnosis or treatment of
the underlying cause of ACD might be beyond the scope of GPs’ focus, for example, the diagnosis
or treatment of malignancies. In addition, for 12% of patients without a clear cause of ACD, no addi-
tional investigations were requested. For most of these patients, no reason was documented for dis-
regarding further investigations. However, GPs may have considered these patients too vulnerable
for extensive tests due to, for example, advanced age and/or comorbidities, or the lack of conse-
quences in these frail patients.24
Comparable studies analysing the underlying causes of ACD have investigated hospitalised popu-
lations, whereas no data are available for community-dwelling adults with ACD. In this study, the
most common underlying causes of ACD were infections, autoimmune inflammation, and malignan-
cies; this is in line with data from hospitalised patients with ACD.4,25,26 However, compared with the
present study population, a markedly higher prevalence of renal insufficiency was reported among
hospitalised patients with ACD.3,25 This might be due to selection bias in the present study popula-
tion; the transmural project separated renal anaemia as a distinct category of anemia, resulting in
less renal insufficiency in this ACD patient group. In addition, since only patients with newly diag-
nosed anaemia (that is, no anaemia in the preceding 2 years) were included, this probably excluded
patients frequently hospitalised and those already being treated by, for instance, a nephrologist.
In this study, the diagnostic strategy of GPs was in accordance with the current Dutch recommen-
dations in 77% of the patients with newly diagnosed ACD. Patients presenting with high ferritin
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levels (>324 mg/l) were more often treated according to these recommendations. Since increased
ferritin is a diagnostic parameter for ACD, elevated levels of ferritin might be an alarm symptom for
GPs, prompting them to more frequently perform additional investigations. In addition, more
increased ferritin levels might exclude iron deficiency more clearly, thereby preventing unnecessary
oral iron supplementation. A trend was observed towards less frequent implementation of the rec-
ommendations in older patients and patients with more severe anaemia. In older patients, multiple
diseases and/or comorbidities often determine the clinical presentation (that is, health status). There-
fore, especially in these patients, GPs might decide to forgo additional investigations. Patients with
severe anaemia may be rapidly treated with oral iron supplementation to elevate haemoglobin lev-
els. However, this is not recommended in patients with ACD.
Nevertheless, about 13% of the patients in this study still received oral iron supplementation as
part of their treatment, even though no benefit is expected due to enhanced levels of hepcidin and,
therefore, reduced oral iron absorption.2,14–16 In this study, severe anaemia and minimally reduced
ferritin levels (i.e. <324 mg/l) are associated with increased oral iron prescription by GPs. The associa-
tion of minimally reduced ferritin levels and the more frequent prescription of oral iron supplementa-
tion might be caused by the absence of a definite ferritin cut-off value defining iron
deficiency.16,21 The effect of oral iron supplementation in patients with ACD might cause unneces-
sary side effects and drug–drug interactions, and can lead to unnecessary (although small) costs.27,28
Implications for practice
To the authors’ knowledge, this is the first study to explore and describe additional investigations to
establish underlying causes in patients with newly diagnosed ACD in primary care. In these patients,
infections, autoimmune diseases, and malignancies were the most frequently occurring underlying
causes. Oral iron supplementation, which is not indicated in ACD patients, needs to be abandoned
in primary care to prevent unnecessary side effects and costs, as well as possible drug–drug interac-
tions. The information emerging from this study and data on the prevalence of the underlying causes
in primary care may lead to more targeted investigations and, potentially, to a more targeted diag-
nosis and more appropriate treatment.
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